Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and joint health with emicizumab in pediatric hemophilia A without FVIII inhibitors
jRCT1080224629Phase 4Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Long-term safety of emicizumab and Joint health outcomes. Started Apr 2019; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT1080224629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224629.